Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Blood Test Diagnoses Cause of Kidney Failure

By Labmedica International staff writers
Posted on 01 Feb 2012
Discoveries about the basic workings of endothelial cells could lead to a diagnostic test for the serious kidney disease known as hemolytic uremic syndrome (HUS).

HUS is a potentially life-threatening condition and often occurs after gastrointestinal infection with Escherichia coli O157:H7, which produces Shiga toxins (Stx) that cause hemolytic anemia, thrombocytopenia, and renal injury.

Scientists at University of Toronto (ON, Canada) discovered a biological pathway never before known to have played a role in the development of HUS. Specifically, they found that the toxin can increase the level of a chemokine, namely stromal cell-derived factor-1 (SDF-1), and its receptor, C-X-C chemokine receptor type 4 (CXCR4). Chemokines are small secreted proteins that stimulate cells to move or migrate. CXCR4 was already known to stimulate the release and migration of the precursors of white blood cells from bone marrow, to change how blood vessels grow and to help the AIDS virus enter cells.

Blood tests were performed on children with E. coli and all measurements of SDF-1 were performed on blinded samples by a sandwich enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN, USA). The results indicated that those who went on to develop HUS had as much as four times higher levels of the protein SDF-1, than other children with E. coli who did not go on to develop HUS. This suggests that a blood test could be used to predict who is most likely to develop the potentially fatal HUS, meaning they could be monitored more closely. The scientists found that too much communication between SDF-1 and CXCR4 molecules can also impact the development of HUS in animals and humans.

Philip A. Marsden, MD, FRCPC, who is a nephrologist at Saint Michael’s Hospital (Toronto, ON, Canada) and senior author of the study, said, "A safe water supply and clean food supply chain is the most important step in preventing HUS caused by E. coli. If we can measure SDF-1 levels in real time during an E. coli outbreak and confirm these findings, then we have a strong case for a trial of CXCR4 antagonists in patients with toxin-producing E. coli to see if it prevents or improves cases of HUS.” The study was published on January 9, 2012, in the Journal of Clinical Investigation.

Related Links:
University of Toronto
R&D Systems
Saint Michael’s Hospital


Sekisui Diagnostics
PURITAN MEDICAL
EUROIMMUN AG
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image: The ADVIA Centaur XPT Immunoassay System delivers the results that clinicians depend upon for accurate diagnoses and better patient care (Photo courtesy of Siemens Healthcare).

Introduction of New Central Laboratory Clinical Analyzers Highlights Recent Lab Equipment Exposition

An impressive array of new automated analyzers for central diagnostic laboratories was unveiled at a recent lab equipment trade fair. The IFCC WorldLab exposition held June 22-26, 2014, in Istanbul... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.